ClinicalTrials.gg
RecruitingNCT07552610Updated Jun 25, 2026

Sivelestat Sodium as an Adjunct to Endovascular Thrombectomy for Acute Anterior Circulation Large-Vessel Occlusion

An interventional study of Sivelestat sodium and Placebo in Acute Ischemic Stroke, Large Vessel Occlusion and Thrombectomy, sponsored by Xuanwu Hospital, Beijing. Recruiting at 2 sites in China. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-06-25.

Sponsored by Xuanwu Hospital, Beijing · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Jun 2026; still recruiting 5 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
868
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 52 studies in Ischemic Stroke by Xuanwu Hospital, Beijing — 30 open to participants now, 31 under way, 2 of them phase 3. Ischemic Stroke · Xuanwu Hospital, Beijing.

Planned enrollment
6th of 28
868 · median 325
Started
2026
with 9 others
No phase
14 of 52
10 open now
Primary completion
2029-05
later than 27 of 30 live
Registered
47th of 52
by date

Among the 52 studies in Ischemic Stroke by Xuanwu Hospital, Beijing, this one is the 6th largest by planned enrollment of the 28 interventional ones that give a count, is one of 10 that started in 2026, is one of 14 with no phase, reaches primary completion later than 27 of the 30 other live ones, and was the 47th registered.

Ischemic Stroke

2,629 studies on the registry are indexed under Ischemic Stroke; 983 are open to participants now.

Browse Ischemic Stroke studies →

Open to participants now

30 of the 52 studies in Ischemic Stroke by Xuanwu Hospital, Beijing are open now, in 1 country. Recruiting first, the newest first:

24 more — sign in →

By country, each count listing its studies:

All 30 open studies →

Where they have run

Who these studies take

Of the 668 Ischemic Stroke studies recruiting now, 403 (60%) set no upper age limit and 62 (9%) stop at 75 or younger; 27 take children under 18; 41 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 52 studies in Ischemic Stroke by Xuanwu Hospital, Beijing, or all of them as a file.
02

Study summary

Stroke remains a major global health burden, with acute ischemic stroke (AIS) accounting for more than 65% of all cases. Endovascular thrombectomy (EVT) has been established as a standard treatment for large vessel occlusion (LVO) stroke; however, "futile recanalization" remains common, with many patients failing to achieve favorable functional outcomes despite successful vessel reperfusion. Increasing evidence indicates that neutrophils and neutrophil extracellular traps (NETs) play important roles in post-reperfusion inflammation, thrombosis, and microcirculatory dysfunction, which may contribute to thrombolysis resistance and poor prognosis. Neutrophil elastase (NE), a key component associated with NETs, may further aggravate vascular injury and thrombus formation.

Sivelestat Sodium is a selective NE inhibitor that has demonstrated anti-inflammatory and organ-protective effects in patients with acute respiratory distress syndrome and in experimental models of cerebral ischemia. It may help preserve blood-brain barrier integrity, reduce brain edema, and improve neurological outcomes. Based on these findings, this study is designed as a multicenter, randomized, double-blind, placebo-controlled clinical trial to evaluate the efficacy and safety of sivelestat sodium as an adjunct to EVT in patients with acute anterior circulation large-vessel occlusive stroke within 24 hours of onset. The results of this study are expected to provide further clinical evidence for anti-inflammatory adjunctive treatment strategies aimed at reducing futile recanalization and improving functional outcomes in AIS.

03

Conditions studied

  • Acute Ischemic Stroke
  • Large Vessel Occlusion
  • Thrombectomy
  • Neutrophil Extracellular Trap Formation

Browse trials for

Keywords

  • Endovascular Thrombectomy
  • Sivelestat Sodium
  • Neutrophil elastase
04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 1.Symptoms and signs consistent with focal ischemia in the anterior circulation;
  • 2.Large vessel occlusion of the anterior circulation (internal carotid artery, M1/M2 segment of the middle cerebral artery) confirmed by CTA/MRA/DSA;
  • 3.Undergoing mechanical thrombectomy;
  • 4.Age between 18-80 years, both male and female;
  • 5.Pre-stroke modified Rankin Scale (mRS) score ≤1;
  • 6.Time from symptom onset to thrombectomy ≤24 hours, including wake-up stroke or unwitnessed stroke; symptom onset is defined as the "last known well" (LKW);
  • 7.National Institutes of Health Stroke Scale (NIHSS) score ≥6 at admission;
  • 8.ASPECTS ≥3 for anterior circulation occlusion;
  • 9.Written provided by the patient or their legal representative.

Exclusion criteria

Exclusion Criteria:

  • 1.Simultaneous acute occlusion of both the anterior and posterior circulation, or bilateral acute large-vessel occlusion in the anterior circulation;
  • 2.Failure to obtain a baseline NIHSS score before sedation or intubation by a neurologist or emergency physician;
  • 3.Seizure at stroke onset that precludes assessment of the baseline NIHSS score;
  • 4.Bilateral dilated pupils;
  • 5.Known allergy to sivelestat sodium or any of its ;
  • 6.Severe allergy or absolute to iodinated contrast agents;
  • 7.Systolic blood pressure >185 mmHg or diastolic blood pressure >110 mmHg that cannot be controlled with antihypertensive therapy;
  • 8.Blood glucose \<50 mg/dL (2.8 mmol/L) or >400 mg/dL (22.2 mmol/L);
  • 9. count \<50 * 10⁹/L;
  • 10.Hereditary or acquired bleeding tendency, coagulation factor deficiency, current oral anticoagulant use with >1.7, or oral anticoagulant treatment within the previous 48 hours;
  • 11.Severe renal failure, defined as serum creatinine >3.0 mg/dL (265.2 μmol/L), (GFR) \<30 mL/min, or requirement for hemodialysis or peritoneal dialysis;
  • 12.Inability to complete the 90-day follow-up (e.g., no fixed residence or overseas patients);
  • 13.Suspected vasculitis or septic embolism;
  • 14.Suspected aortic dissection;
  • 15.Evidence of intracranial tumor (except small meningioma), acute intracranial hemorrhage, tumor, or arteriovenous malformation;
  • 16.Significant mass effect with midline shift;
  • 17.Evidence of internal carotid artery dissection causing flow limitation;
  • 18.Neurological disease or psychiatric disorder that may interfere with evaluation of the patient's condition;
  • 19.Pregnant or breastfeeding women;
  • 20.Confirmed rheumatic or disease with long-term use of or ;
  • 21.Current treatment with chemotherapy or other immunomodulatory agents (e.g., recombinant human granulocyte colony-stimulating factor, Xuebijing, or ulinastatin);
  • 22.Participation in another clinical trial that may interfere with the results of this study;
  • 23.Any other condition that, in the opinion of the investigator, would make the patient unsuitable for participation or may pose a significant risk to the patient.
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
868 participants (estimated)

Study arms

  • Experimental
    Sivelestat Sodium + Endovascular Thrombectomy

    Participants randomized to the experimental arm will receive sivelestat sodium injection in addition to standard endovascular thrombectomy (EVT). Sivelestat sodium will be initiated within 2 hours after randomization and administered once daily until Day 7 after randomization or hospital discharge, whichever occurs first. The daily dose is 4.8 mg/kg, given by continuous infusion using a microinfusion pump or by intravenous drip. EVT will be performed according to standard clinical practice using NMPA-approved thrombectomy devices.

    Drug: Sivelestat sodium · Procedure: Endovascular Thrombectomy

  • Placebo comparator
    Placebo + Endovascular Thrombectomy

    Participants randomized to the control arm will receive placebo in addition to standard EVT. The placebo does not contain sivelestat sodium and will be administered in the same manner as the investigational product, beginning within 2 hours after randomization and continuing once daily until Day 7 after randomization or hospital discharge, whichever occurs first. The placebo is matched to sivelestat sodium in appearance, packaging, labeling, and method of administration to maintain blinding. EVT will be performed according to standard clinical practice.

    Drug: Placebo · Procedure: Endovascular Thrombectomy

Interventions

  • DrugSivelestat sodium tetrahydrateStudies of Sivelestat sodium tetrahydrateSivelestat sodium tetrahydrate pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Sivelestat sodium is a selective neutrophil elastase inhibitor administered as an adjunctive treatment to endovascular thrombectomy in this study. Treatment will be initiated within 2 hours after randomization and continued once daily until Day 7 after randomization or hospital discharge, whichever occurs first. The daily dose is 4.8 mg/kg, administered by continuous intravenous infusion using a microinfusion pump or by intravenous drip.

  • DrugPlacebo

    The placebo does not contain sivelestat sodium and consists of the same excipients as the investigational product without the active ingredient. It will be administered in the same manner, timing, and schedule as sivelestat sodium, beginning within 2 hours after randomization and continuing once daily until Day 7 after randomization or hospital discharge, whichever occurs first, in order to maintain blinding.

  • ProcedureEndovascular Thrombectomy

    Endovascular thrombectomy will be performed according to standard clinical practice using NMPA-approved thrombectomy devices. First-line techniques may include aspiration thrombectomy, stent retriever thrombectomy, or a combined approach, with rescue procedures permitted when necessary at the investigator's discretion.

06

What researchers measure

Primary outcomes

  1. Rate of modified Rankin Scale (mRS) score of 0-2

    The mRS score range from 0 (no disability) to 6 (death)

    Time frame: 90 days (±7 days) after randomization

Secondary outcomes

  1. Rate of modified Rankin Scale (mRS) score of 0-1

    The mRS score range from 0 (no disability) to 6 (death)

    Time frame: 90 days (±7 days) after randomization

  2. Rate of mRS score of 0-3

    The mRS score range from 0 (no disability) to 6 (death)

    Time frame: 90 days (±7 days) after randomization

  3. Proportional distribution of modified Rankin Score

    The mRS score range from 0 (no disability) to 6 (death)

    Time frame: 90 days (±7 days) after randomization

  4. Improvement of the National Institutes of Health Stroke Scale (NIHSS) score

    The NIHSS score range from 0 (no deficit) to 42 (maximum deficit)

    Time frame: 48 hours (±12 hours) after randomization

  5. Rate of early neurological improvement

    Early neurological improvement, defined as an NIHSS score of 0-1 at 48 hours or a reduction of ≥4 points from baseline.

    Time frame: 48 hours (±12 hours) after randomization

  6. Improvement of the NIHSS score

    The NIHSS score range from 0 (no deficit) to 42 (maximum deficit)

    Time frame: 7 days (±1 days) after randomization or discharge

  7. EQ-5D-5L

    The EQ-5D 5-Levels (EQ-5D-5L) range from 5 (no problems) to 25 (extreme problems), which deceased patients have a utility of 0.

    Time frame: 90 days (±7 days) after randomization

  8. Barthel Index

    The Barthel Index range from 0 (severe disability) to 100 (no disability)

    Time frame: 90 days (±7 days) after randomization

  9. Rate of intracranial hemorrhage (ICH)

    Any intracranial hemorrhage confirmed by imaging

    Time frame: Within 48 hours after randomization

  10. Rate of symptomatic intracranial hemorrhage (sICH)

    The sICH was assessed based on the Heidelberg Bleeding Classification, defined as 1) ≥4 points total NIHSS at the time of diagnosis compared to immediately before worsening; 2) ≥2 point in one NIHSS category. The rationale for this is to capture new hemorrhages that produce new neurological symptoms, making them clearly symptomatic but not causing worsening in the original stroke territory; 3) Leading to intubation/hemicraniectomy/EVD placement or other major medical/surgical intervention; 4) Absence of alternative explanation for deterioration.

    Time frame: Within 48 hours after randomization

  11. All-cause mortality

    Death is defined as a mRS score of 6

    Time frame: 90 days (±7 days) after randomization

07

Study locations

2 of 2 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2026 (actual). Primary completion is estimated for May 2029, 35 months after the start.

Of 576 non-industry interventional studies with no phase under Ischemic Stroke, half reached primary completion within 28 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 48. This study's planned 35 months is above that.

Counting every sponsor, half of 656 studies reached it within 27 months; a quarter within 14 and three quarters within 48.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 20, 2026
First posted
Apr 27, 2026
StartActual
Jun 22, 2026
Primary completionEst.
May 31, 2029
CompletionEst.
May 31, 2029
Last update
Jun 25, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 25, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07552610
Responsible party
Sponsor
First posted
Apr 27, 2026
Start date
Jun 22, 2026
Primary completion
May 31, 2029 (estimated)
Completion
May 31, 2029 (estimated)
Last update
Jun 25, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Sivelestat sodium tetrahydrate

Start the discussion